Effect and safety of febuxotant versus allopurinol in reducing serum urate in subjects with hyperuricemia and gout:a multi-center,randomized,double-blind,parallel controlled trail

WANG Li-ying,ZHAO Yan,ZHENG Yi,LI Xiao-xia,ZHANG Xiao,XU Jian-hua,WU Hua-xiang,HU Shao-xian,ZHAO Yin-huan,ZHANG Feng-xiao,ZHOU Bin,SU Hou-heng,XIAO Zheng-yu,SUN Rui-hua,WANG Guo-chun
DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2013.07.011
2013-01-01
Abstract:Objective To compare urate-lowering(UL) efficacy and safety of daily febuxotant versus allopurinol and in subjects with gout and serum urate(SUA)≥480 μmol/L in six-month trial.Methods Subjects(n=486) were randomized to febuxotant 40 mg or 80 mg or allopurinol 300 mg.Endpoints included the proportion of all subject with sUA≤360 μmol/L and safety assessment.Results In febuxotant 40 mg,80 mg and allopurinol group,primary endpoint was achieved in 49.06%,65.38% and 43.67%.Febuxotant 40 mg UL was statistically non-inferior to allopurinol,but febuxotant 80 mg was superior to both(P<0.0001).Rates of AEs did not differ aross treatment group.Conclusions Febuxotant 40 mg group UL efficacy is similar to allopurinol group,febuxotant 80 mg group UL efficacy is better than both febuxotant 40 mg group and allopurinol group.Febuxotant 40 mg daily and febuxotant 80 mg daily treatment for 24 weeks is well tolerated.
What problem does this paper attempt to address?